Physician profile

Gregory A Lundeen

Foot and Ankle Surgery · Reno, NV

NPI 1720036270

$301,436.46

in general payments reported to CMS, 2019-2025

36 companies · $49K in 2025

The $49K reported for 2025 was more than what 90% of Foot and Ankle Surgery providers received nationally (typical 2025 total: $1,200).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$89,400.00
Travel and Lodging$14,958.73
Food and Beverage$7,163.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $237,686.96 2019-2025 Salvation, Hoffmann, Prostep
Encore Medical, Lp $33,532.57 2021-2025
Trilliant Surgical LLC. $20,037.18 2021-2025 13mm Star E+ Sliding Core Star Total Ankle
Medshape, INC. $4,008.23 2021-2025 Dynanail, Dynanail Helix, Washer, 15 Mm
Exactech, INC. $1,070.23 2020-2025
Goode Surgical INC $998.08 2025
Bone Support INC. $527.43 2024-2025 Cerament G, Ceramentbone Void Filler
Orthofix Medical, INC. $297.85 2024-2025 Physio-Stim, Accelstim
Zimmer Biomet Holdings, INC. $226.15 2019-2022
Solventum Corporation $213.64 2024-2025 V.A.C.Ulta, Prevena, V.A.C. Veraflo
Vertex Pharmaceuticals Incorporated $192.68 2024-2025
Acell, INC. $192.12 2019-2020
Musculoskeletal Transplant Foundation INC. $181.81 2022-2023
Treace Medical Concepts, INC. $176.30 2024
Smith+Nephew, INC. $175.77 2022-2025 Bone Anchors With Arthroscopic Delivery System
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Alafair Biosciences, INC. $168.65 2025 Versawrap
Sequoia Surgical, INC. $162.27 2019-2020
Curvebeam LLC $160.37 2024
Davol INC. $153.27 2022
Avita Medical Americas, LLC $140.38 2025 Permeaderm, Recell, Cohealyx
Kci USA, INC. $136.68 2021-2022
Kerecis Limited $134.20 2023 Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide
Amniox Medical, INC. $133.02 2020
Paragon 28, INC. $126.66 2025 Additive Orthopedics
Biotissue Holdings INC. $104.80 2022-2023
3d Systems $103.18 2021
Linvatec Corporation $98.01 2024 Biobrace 23mm
Baudax Bio INC. $84.05 2021-2022
Bioventus LLC $60.92 2024-2025 Exogen Ultrasound Bone Healing System
Depuy Synthes Sales INC. $53.86 2019
Polynovo North America LLC $23.40 2024 Novosorb Btm
Arthrex, INC. $23.15 2025
Si-Bone, INC. $21.63 2023
Integra Lifesciences Corporation $16.48 2022
Evolution Surgical, INC $14.48 2024

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$137,750.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gregory A Lundeen

$301,436.46

in general payments reported 2019-2025

Years
2019-2025
Top company
Stryker Corporation
Context
The $49K reported for 2025 was more than what 90% of Foot and Ankle Surgery providers received nationally (typical 2025 total: $1,200).

https://glasscript.com/doctor/214274/gregory-a-lundeen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.